A case study of a patient with platelet transfusion refractoriness (PTR) combined with human leucocyte antigen (HLA) antibody positivity during hepatic arterial infusion chemotherapy in conjunction with the ‘atezolizumab plus bevacizumab’ regimen.

MLA

Xie, Yawen, et al. “A Case Study of a Patient with Platelet Transfusion Refractoriness (PTR) Combined with Human Leucocyte Antigen (HLA) Antibody Positivity during Hepatic Arterial Infusion Chemotherapy in Conjunction with the ‘Atezolizumab plus Bevacizumab’ Regimen.” Nursing in Critical Care, July 2024, p. 1. EBSCOhost, https://doi.org/10.1111/nicc.13118.

APA

Xie, Y., Huang, Y., & Liu, S. (2024). A case study of a patient with platelet transfusion refractoriness (PTR) combined with human leucocyte antigen (HLA) antibody positivity during hepatic arterial infusion chemotherapy in conjunction with the ‘atezolizumab plus bevacizumab’ regimen. Nursing in Critical Care, 1. https://doi.org/10.1111/nicc.13118

Chicago

Xie, Yawen, Yanxia Huang, and Shuyue Liu. 2024. “A Case Study of a Patient with Platelet Transfusion Refractoriness (PTR) Combined with Human Leucocyte Antigen (HLA) Antibody Positivity during Hepatic Arterial Infusion Chemotherapy in Conjunction with the ‘Atezolizumab plus Bevacizumab’ Regimen.” Nursing in Critical Care, July, 1. doi:10.1111/nicc.13118.